Researchers criticise EMA over trial reporting and access to "commercial" raw data
This article was originally published in SRA
The European Medicines Agency is again under fire for the way it makes public clinical trial-related information. Researchers writing in the BMJ have criticised how the agency reports Phase III trial results in its European public assessment reports. The criticism comes shortly after the agency defended itself against another BMJ article accusing regulators of putting drug company profits ahead of patient wellbeing when it comes to allowing access to unpublished trial reports.